These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study. Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299 [TBL] [Abstract][Full Text] [Related]
11. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288 [TBL] [Abstract][Full Text] [Related]
12. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues. Frisch ES; Pretzsch R; Weber MS Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738 [TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Auguste P; Colquitt J; Connock M; Loveman E; Court R; Ciccarelli O; Counsell C; Armoiry X Pharmacoeconomics; 2020 Jun; 38(6):527-536. PubMed ID: 32048205 [TBL] [Abstract][Full Text] [Related]
18. Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Havla J; Hohlfeld R Neurotherapeutics; 2022 Apr; 19(3):774-784. PubMed ID: 35289375 [TBL] [Abstract][Full Text] [Related]
19. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study. Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559 [TBL] [Abstract][Full Text] [Related]
20. [Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab]. Boyko OV; Choroshilova II; Petrov SV; Melnikov MV; Boyko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):120-127. PubMed ID: 31934997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]